學門類別
哈佛
- General Management
- Marketing
- Entrepreneurship
- International Business
- Accounting
- Finance
- Operations Management
- Strategy
- Human Resource Management
- Social Enterprise
- Business Ethics
- Organizational Behavior
- Information Technology
- Negotiation
- Business & Government Relations
- Service Management
- Sales
- Economics
- Teaching & the Case Method
最新個案
- A practical guide to SEC ï¬nancial reporting and disclosures for successful regulatory crowdfunding
- Quality shareholders versus transient investors: The alarming case of product recalls
- The Health Equity Accelerator at Boston Medical Center
- Monosha Biotech: Growth Challenges of a Social Enterprise Brand
- Assessing the Value of Unifying and De-duplicating Customer Data, Spreadsheet Supplement
- Building an AI First Snack Company: A Hands-on Generative AI Exercise, Data Supplement
- Building an AI First Snack Company: A Hands-on Generative AI Exercise
- Board Director Dilemmas: The Tradeoffs of Board Selection
- Barbie: Reviving a Cultural Icon at Mattel (Abridged)
- Happiness Capital: A Hundred-Year-Old Family Business's Quest to Create Happiness
Artepharm: Commercialising the Malaria Cure in Africa
內容大綱
This case is set January 2019. Song Jianping is senior advisor to Chinese pharmaceutical firm Artepharm, which has been engaging in malaria elimination in Africa since 2003. With a deep understanding of the African market, the company has developed an innovative approach to malaria elimination, stemming from traditional Chinese medicine. It created a combination drug marketed as Artequick and put forward an innovative programme called Fast Elimination of Malaria by Source Eradication (FEMSE). Despite the success of the FEMSE programme, which had been tested in the Comoros and eliminated about 95% of the malaria cases there, Artepharm had been facing a lot of challenges in commercialising its innovative and effective solution. These challenges include a lack of presence in the public market which was dominated by multinational corporations such as Novartis and generic pharmaceutical companies from India. Artepharm recognises that it has realised only a small fraction of the potential sales of antimalarial drugs on the African continent. Song is thinking about the next steps to increase Artequick sales, so that the company can become profitable and not rely on funding from its parent company and the Chinese government.